The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: Software tool

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Estill, Janne ^a   Salazar Vizcaya, Luisa ^a   Blaser, Nello ^a   Egger, Matthias ^a,b   Keiser, Olivia ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; DRUG MONITORING; DRUG SUBSTITUTION; ELECTRONIC SPREADSHEET; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MATHEMATICAL MODEL; POINT OF CARE TESTING; SENSITIVITY ANALYSIS; VIRUS LOAD; ADOLESCENT; ADULT; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; MALE; MIDDLE AGED; PROCEDURES; SOFTWARE; THEORETICAL MODEL; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; SOFTWARE; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925584273     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119299     Document Type: Article

References (39)

1. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Geneva, Switzerland: World Health Organization. Available: http://apps.who.int/iris/bitstream/10665/85321/1/ 9789241505727-eng.pdf?ua=1. Accessed 18 December 2014.
2. Estill J, Aubrière C, Egger M, Johnson L, Wood R, Garone D, et al. (2012) Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. AIDS 26: 1403-1413. doi: 10.1097/QAD.0b013e3283536988 PMID: 22421243
3. Joint United Nations Programme on HIV/AIDS (UNAIDS) and Médecines Sans Frontières (MSF) (2012) Speed up scale-up: Strategies, tools and policies to get the best HIV treatment to more people, sooner. UNAIDS; MSF. Available: http://www.msfaccess.org/sites/default/files/MSF-assets/HIV- AIDS/Docs/AIDS-report-SpeedUpScaleUp-ENG-2012.pdf. Accessed 18 December 2014.
4. Estill J, Egger M, Johnson LF, Gsponer T, Wandeler G, Davies MA, et al. (2013) Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study. PLoS One 8: e57611. doi: 10.1371/journal.pone.0057611 PMID: 23469035
5. Estill J, Egger M, Blaser N, Salazar-Vizcaya L, Garone D, Wood R, et al. (2013) Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study. AIDS 27: 1483-1492. doi: 10.1097/QAD.0b013e328360a4e5 PMID: 23462219
6. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD (2008) Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371: 1443-1451. doi: 10.1016/S0140-6736 (08)60624-8 PMID: 18440426
7. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. (2011) Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 343: d6792. doi: 10.1136/bmj.d6792 PMID: 22074711
8. Kahn JG, Marseille E, Moore D, Bunnell R, Were W, Degerman R, et al. (2011) CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ 343: d6884. doi: 10.1136/bmj.d6884 PMID: 22074713
9. UNITAID (2013) HIV/AIDS Diagnostics Technology Landscape. Semi-annual update. (2013). Geneva, Switzerland: UNITAID. Available: http://www.unitaid.eu/images/UNITAID-2013-Semi-annual- Update-HIV-Diagnostics-Technology-Landscape.pdf. Accessed 18 December 2014.
10. Rousseau C (2012) HIV Point of Care Viral Load Tests Development: Request for Applications. Available: http://mat1.gtimg.com/gongyi/2012/enzhenduandahui/16ChristineRousseau.pdf. Accessed 18 December 2014.
11. Bonner K, Mezochow A, Roberts T, Ford N, Cohn J (2013) Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr 64: 74-78. doi: 10.1097/QAI. 0b013e31829f05ac PMID: 23774877
12. Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, et al. (2014) High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis 58: 1023-1026. doi: 10.1093/cid/cit933 PMID: 24352348
13. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, et al. (2009) Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during firstline antiretroviral therapy in South Africa. Clin Infect Dis 49: 1928-1935. doi: 10.1086/648444 PMID: 19911963
14. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, et al. (2007) Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 12: 83-88. PMID: 17503751
15. Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard GD, et al. (2014) Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon. J Antimicrob Chemother. In press.
16. Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, et al. (2007) Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials 8: 282-292. PMID: 17956829
17. Salazar Vizcaya L, Blaser N, Gsponer T (2014) gems: Generalized multistate simulation model. Available: http://cran.r-project.org/web/packages/gems/index.html. Accessed 18 December 2014.
18. Blaser N, Salazar-Vizcaya L, Estill J, Zahnd C, Kalesan B, Egger M, et al. (2014) gems: an R package for Simulating from Disease Progression Models. J Stat Softw. In press. PMID: 25400517
19. Estill J, Tweya H, Egger M, Wandeler G, Feldacker C, Johnson LF, et al. (2014) Tracing of patients lost to follow-up and HIV transmission: Mathematical modeling study based on two large ART programs in Malawi. J Acquir Immune Defic Syndr. 65: e179-e186. doi: 10.1097/QAI.0000000000000075 PMID: 24326599
20. Brinkhof MWG, Boulle A, Weigel R, Messou E, Mathers C, Orrell C, et al. (2009) Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med 6: e1000066. doi: 10.1371/journal.pmed.1000066 PMID: 19399157
21. Actuarial Society of South Africa, AIDS Committee (2011) ASSA2008 Model. Actuarial Society of South Africa. Available: http://www.actuarialsociety.org.za/Societyactivities/CommitteeActivities/ AidsCommittee/Models.aspx. Accessed 18 December 2014.
22. World Health Organization. Global Burden of Disease 2004 update: Disability weights for diseases and conditions. Geneva, Switzerland: World Health Organization. Available: http://www.who.int/healthinfo/ global-burden-disease/GBD2004-DisabilityWeights.pdf. Accessed 18 December 2014.s
23. World Health Organization, Commission on Macroeconomics and Health (2001) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland: World Health Organization. Available: http://whqlibdoc.who.int/ publications/2001/924154550x.pdf. Accessed 18 December 2014.
24. International Monetary Fund (2014) World Economic and Financial Surveys: World Ecenomic Outlook Database. International Monetary Fund. Available: http://www.imf.org/external/pubs/ft/weo/2014/01/ weodata/index.aspx. Accessed 18 December 2014.
25. Walensky RP, Ciaranello AL, Park J-E, Freedberg KA (2010) Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 51: 85 -92. doi: 10.1086/ 653119 PMID: 20482371
26. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK (2008) Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 168: 1910-1918. doi: 10.1001/archinternmed.2008.1 PMID: 18809819
27. Bishai D, Colchero A, Durack DT (2007) The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 21: 1333-1340. PMID: 17545710
28. Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, Santas CC (2007) Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 46: 91-100. PMID: 17621241
29. Braithwaite RS, Nucifora KA, Yiannoutsos CT, Musick B, Kimaiyo S, Diero L, et al. (2011) Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc 14: 38. doi: 10.1186/1758-2652-14-38 PMID: 21801434
30. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM (2012) Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 26: 1663-1672. PMID: 22695297
31. Keebler D, Revill P, Braithwaite RS, Phillips AN, Blaser N, Borquez A, et al. (2014) Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob Health 2: e35-e43. doi: 10.1016/S2214-109X(13)70048-2 PMID: 25104633
32. Centers for Disease Control and Prevention (CDC) (2013) Impact of an innovative approach to prevent mother-to-child transmission of HIV-Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep 62: 148-151. PMID: 23446514
33. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57. doi: 10.1016/S0140-6736(08)61697-9 PMID: 19038438
34. Wandeler G, Keiser O, Pfeiffer K, Pestilli S, Fritz C, Labhardt ND, et al. (2012) Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr 59: e9-e16. doi: 10. 1097/QAI.0b013e31823edb6a PMID: 22067665
35. Tweya H, Feldacker C, Estill J, Jahn A, Ng'ambi W, Ben-Smith A, et al. (2013) Are they really lost? "true" status and reasons for treatment discontinuation among HIV infected patients on antiretroviral therapy considered lost to follow up in Urban Malawi. PLoS One 8: e75761. doi: 10.1371/journal.pone. 0075761 PMID: 24086627
36. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, et al. (2011) Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 378: 1572-1579. doi: 10.1016/S0140-6736(11)61052-0 PMID: 21951656
37. Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, et al. (2010) Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 54: 258-268. doi: 10.1097/QAI.0b013e3181d0db97 PMID: 20404739
38. Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, et al. (2010) Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a modelbased analysis. PLoS Med 7: e1000382. doi: 10.1371/journal.pmed.1000382 PMID: 21209794
39. Egger M, Spycher BD, Sidle J, Weigel R, Geng EH, Fox MP, et al. (2011) Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med 8: e1000390. doi: 10.1371/journal.pmed.1000390 PMID: 21267057